<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>MP</title>
  <meta name="description" content="MP">
  <meta name="generator" content="bookdown 0.7 and GitBook 2.6.7">

  <meta property="og:title" content="MP" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="MP" />
  
  
  

<meta name="author" content="pqi">



  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="sbrt.html">
<link rel="next" href="implants.html">
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="style.css" type="text/css" />
<link rel="stylesheet" href="font-awesome.min.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">A Minimal Book Example</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome</a></li>
<li class="chapter" data-level="1" data-path="introduction.html"><a href="introduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a><ul>
<li class="chapter" data-level="1.1" data-path="introduction.html"><a href="introduction.html#constant"><i class="fa fa-check"></i><b>1.1</b> Physics constants</a></li>
<li class="chapter" data-level="1.2" data-path="introduction.html"><a href="introduction.html#atomic-rep"><i class="fa fa-check"></i><b>1.2</b> Atomic Representation</a></li>
<li class="chapter" data-level="1.3" data-path="introduction.html"><a href="introduction.html#stability"><i class="fa fa-check"></i><b>1.3</b> Stability</a></li>
<li class="chapter" data-level="1.4" data-path="introduction.html"><a href="introduction.html#mass-defect"><i class="fa fa-check"></i><b>1.4</b> Mass Defect</a></li>
<li class="chapter" data-level="1.5" data-path="introduction.html"><a href="introduction.html#einstein"><i class="fa fa-check"></i><b>1.5</b> High energy charged particles</a></li>
<li class="chapter" data-level="1.6" data-path="introduction.html"><a href="introduction.html#high-energy-photons"><i class="fa fa-check"></i><b>1.6</b> High energy photons</a></li>
<li class="chapter" data-level="1.7" data-path="introduction.html"><a href="introduction.html#electron-shell"><i class="fa fa-check"></i><b>1.7</b> Electron Shell</a></li>
<li class="chapter" data-level="1.8" data-path="introduction.html"><a href="introduction.html#solutions"><i class="fa fa-check"></i><b>1.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="nut.html"><a href="nut.html"><i class="fa fa-check"></i><b>2</b> Nuclear Transformation</a><ul>
<li class="chapter" data-level="2.1" data-path="nut.html"><a href="nut.html#decays"><i class="fa fa-check"></i><b>2.1</b> Nuclear Decay (disintegration)</a><ul>
<li class="chapter" data-level="2.1.1" data-path="nut.html"><a href="nut.html#alpha"><i class="fa fa-check"></i><b>2.1.1</b> Alpha-decay</a></li>
<li class="chapter" data-level="2.1.2" data-path="nut.html"><a href="nut.html#beta"><i class="fa fa-check"></i><b>2.1.2</b> Beta-decay</a></li>
<li class="chapter" data-level="2.1.3" data-path="nut.html"><a href="nut.html#ec"><i class="fa fa-check"></i><b>2.1.3</b> Electron capture</a></li>
<li class="chapter" data-level="2.1.4" data-path="nut.html"><a href="nut.html#gamma"><i class="fa fa-check"></i><b>2.1.4</b> Gamma decay</a></li>
</ul></li>
<li class="chapter" data-level="2.2" data-path="nut.html"><a href="nut.html#activity"><i class="fa fa-check"></i><b>2.2</b> Activity</a></li>
<li class="chapter" data-level="2.3" data-path="nut.html"><a href="nut.html#solutions-1"><i class="fa fa-check"></i><b>2.3</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="prox.html"><a href="prox.html"><i class="fa fa-check"></i><b>3</b> Production of X-rays</a><ul>
<li class="chapter" data-level="3.1" data-path="prox.html"><a href="prox.html#history"><i class="fa fa-check"></i><b>3.1</b> History</a></li>
<li class="chapter" data-level="3.2" data-path="prox.html"><a href="prox.html#conventional-x-ray-tubes"><i class="fa fa-check"></i><b>3.2</b> Conventional x-ray tubes</a><ul>
<li class="chapter" data-level="3.2.1" data-path="prox.html"><a href="prox.html#electron-source-cathode"><i class="fa fa-check"></i><b>3.2.1</b> Electron Source (Cathode)</a></li>
<li class="chapter" data-level="3.2.2" data-path="prox.html"><a href="prox.html#high-voltage"><i class="fa fa-check"></i><b>3.2.2</b> High voltage</a></li>
<li class="chapter" data-level="3.2.3" data-path="prox.html"><a href="prox.html#target-for-x-ray-production"><i class="fa fa-check"></i><b>3.2.3</b> Target for x-ray production</a></li>
<li class="chapter" data-level="3.2.4" data-path="prox.html"><a href="prox.html#target-x-ray-spectra"><i class="fa fa-check"></i><b>3.2.4</b> Target X-ray spectra</a></li>
</ul></li>
<li class="chapter" data-level="3.3" data-path="prox.html"><a href="prox.html#solutions-2"><i class="fa fa-check"></i><b>3.3</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="gene.html"><a href="gene.html"><i class="fa fa-check"></i><b>4</b> Clinical Treatment Generators</a><ul>
<li class="chapter" data-level="4.1" data-path="gene.html"><a href="gene.html#history-1"><i class="fa fa-check"></i><b>4.1</b> History</a></li>
<li class="chapter" data-level="4.2" data-path="gene.html"><a href="gene.html#waveguide"><i class="fa fa-check"></i><b>4.2</b> Waveguide</a></li>
<li class="chapter" data-level="4.3" data-path="gene.html"><a href="gene.html#microwave-amplifier"><i class="fa fa-check"></i><b>4.3</b> Microwave amplifier</a></li>
<li class="chapter" data-level="4.4" data-path="gene.html"><a href="gene.html#microwave-frequency"><i class="fa fa-check"></i><b>4.4</b> Microwave frequency</a></li>
<li class="chapter" data-level="4.5" data-path="gene.html"><a href="gene.html#penumbra"><i class="fa fa-check"></i><b>4.5</b> Penumbra</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="inter.html"><a href="inter.html"><i class="fa fa-check"></i><b>5</b> Interaction</a><ul>
<li class="chapter" data-level="5.1" data-path="inter.html"><a href="inter.html#photo-el"><i class="fa fa-check"></i><b>5.1</b> Photoelectric interactions</a></li>
<li class="chapter" data-level="5.2" data-path="inter.html"><a href="inter.html#compton"><i class="fa fa-check"></i><b>5.2</b> Compton interactions</a></li>
<li class="chapter" data-level="5.3" data-path="inter.html"><a href="inter.html#pair"><i class="fa fa-check"></i><b>5.3</b> Pair production</a></li>
<li class="chapter" data-level="5.4" data-path="inter.html"><a href="inter.html#compton-interactions"><i class="fa fa-check"></i><b>5.4</b> Compton interactions</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="measurement.html"><a href="measurement.html"><i class="fa fa-check"></i><b>6</b> Measurement of Ionizing Radiation</a><ul>
<li class="chapter" data-level="6.1" data-path="measurement.html"><a href="measurement.html#collection-volume"><i class="fa fa-check"></i><b>6.1</b> Collection volume</a></li>
<li class="chapter" data-level="6.2" data-path="measurement.html"><a href="measurement.html#signal-of-an-ion-chamber"><i class="fa fa-check"></i><b>6.2</b> Signal of an ion chamber</a></li>
<li class="chapter" data-level="6.3" data-path="measurement.html"><a href="measurement.html#temperature-and-pressure-correction"><i class="fa fa-check"></i><b>6.3</b> Temperature and pressure correction</a></li>
<li class="chapter" data-level="6.4" data-path="measurement.html"><a href="measurement.html#guard-electrode"><i class="fa fa-check"></i><b>6.4</b> Guard electrode</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="quality.html"><a href="quality.html"><i class="fa fa-check"></i><b>7</b> Quality of X-rays</a></li>
<li class="chapter" data-level="8" data-path="dose.html"><a href="dose.html"><i class="fa fa-check"></i><b>8</b> Absorbed Dose</a><ul>
<li class="chapter" data-level="8.1" data-path="dose.html"><a href="dose.html#optical-density"><i class="fa fa-check"></i><b>8.1</b> Optical density</a></li>
<li class="chapter" data-level="8.2" data-path="dose.html"><a href="dose.html#q9-od"><i class="fa fa-check"></i><b>8.2</b> Q9 OD</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="distribution.html"><a href="distribution.html"><i class="fa fa-check"></i><b>9</b> Dose Distributions</a><ul>
<li class="chapter" data-level="9.1" data-path="distribution.html"><a href="distribution.html#tar"><i class="fa fa-check"></i><b>9.1</b> TAR</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="dosecalc.html"><a href="dosecalc.html"><i class="fa fa-check"></i><b>10</b> Dose calcuation</a></li>
<li class="chapter" data-level="11" data-path="planning1.html"><a href="planning1.html"><i class="fa fa-check"></i><b>11</b> Treatment Planning I: Isodose Distribution and Plan Evaluation</a><ul>
<li class="chapter" data-level="11.1" data-path="planning1.html"><a href="planning1.html#penumbra-1"><i class="fa fa-check"></i><b>11.1</b> Penumbra</a></li>
<li class="chapter" data-level="11.2" data-path="planning1.html"><a href="planning1.html#wedges"><i class="fa fa-check"></i><b>11.2</b> Wedges</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="planning2.html"><a href="planning2.html"><i class="fa fa-check"></i><b>12</b> Treatment Planning II: Patient Data, Corrections, and Setup</a><ul>
<li class="chapter" data-level="12.1" data-path="planning2.html"><a href="planning2.html#inhomogeneity"><i class="fa fa-check"></i><b>12.1</b> Inhomogeneity</a></li>
<li class="chapter" data-level="12.2" data-path="planning2.html"><a href="planning2.html#range"><i class="fa fa-check"></i><b>12.2</b> Range</a></li>
<li class="chapter" data-level="12.3" data-path="planning2.html"><a href="planning2.html#mri"><i class="fa fa-check"></i><b>12.3</b> MRI</a></li>
<li class="chapter" data-level="12.4" data-path="planning2.html"><a href="planning2.html#pet"><i class="fa fa-check"></i><b>12.4</b> PET</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="planning3.html"><a href="planning3.html"><i class="fa fa-check"></i><b>13</b> Treatment Planning III: Field shaping, skin dose, and field separation</a><ul>
<li class="chapter" data-level="13.1" data-path="planning3.html"><a href="planning3.html#hvl"><i class="fa fa-check"></i><b>13.1</b> HVL</a></li>
<li class="chapter" data-level="13.2" data-path="planning3.html"><a href="planning3.html#q2-3-4-and-7-range"><i class="fa fa-check"></i><b>13.2</b> Q2, 3, 4, and 7 Range</a></li>
</ul></li>
<li class="chapter" data-level="14" data-path="electron.html"><a href="electron.html"><i class="fa fa-check"></i><b>14</b> Electron</a><ul>
<li class="chapter" data-level="14.1" data-path="electron.html"><a href="electron.html#history-2"><i class="fa fa-check"></i><b>14.1</b> History</a></li>
<li class="chapter" data-level="14.2" data-path="electron.html"><a href="electron.html#treatment-sites"><i class="fa fa-check"></i><b>14.2</b> Treatment Sites</a></li>
<li class="chapter" data-level="14.3" data-path="electron.html"><a href="electron.html#e-interactions"><i class="fa fa-check"></i><b>14.3</b> Interactions</a></li>
<li class="chapter" data-level="14.4" data-path="electron.html"><a href="electron.html#e-delivery"><i class="fa fa-check"></i><b>14.4</b> Delivery</a></li>
<li class="chapter" data-level="14.5" data-path="electron.html"><a href="electron.html#beam-quality"><i class="fa fa-check"></i><b>14.5</b> Beam quality</a></li>
<li class="chapter" data-level="14.6" data-path="electron.html"><a href="electron.html#internal-shielding"><i class="fa fa-check"></i><b>14.6</b> Internal shielding</a></li>
<li class="chapter" data-level="14.7" data-path="electron.html"><a href="electron.html#total-skin-electron-irradiation-tsei"><i class="fa fa-check"></i><b>14.7</b> Total skin electron irradiation (TSEI)</a></li>
<li class="chapter" data-level="14.8" data-path="electron.html"><a href="electron.html#e-solu"><i class="fa fa-check"></i><b>14.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="brachy.html"><a href="brachy.html"><i class="fa fa-check"></i><b>15</b> Brachytherapy</a><ul>
<li class="chapter" data-level="15.1" data-path="brachy.html"><a href="brachy.html#important-things-to-know"><i class="fa fa-check"></i><b>15.1</b> Important things to know</a></li>
<li class="chapter" data-level="15.2" data-path="brachy.html"><a href="brachy.html#isotopes"><i class="fa fa-check"></i><b>15.2</b> Isotopes</a><ul>
<li class="chapter" data-level="15.2.1" data-path="brachy.html"><a href="brachy.html#radium-sources"><i class="fa fa-check"></i><b>15.2.1</b> Radium sources</a></li>
<li class="chapter" data-level="15.2.2" data-path="brachy.html"><a href="brachy.html#radium-substitutes"><i class="fa fa-check"></i><b>15.2.2</b> Radium substitutes</a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="brachy.html"><a href="brachy.html#source-strength"><i class="fa fa-check"></i><b>15.3</b> Source strength</a><ul>
<li class="chapter" data-level="15.3.1" data-path="brachy.html"><a href="brachy.html#sk"><i class="fa fa-check"></i><b>15.3.1</b> Unit: Air-kerma strength <span class="math inline">\(S_k\)</span></a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="brachy.html"><a href="brachy.html#radiation-dose-from-brachytherpay-sources"><i class="fa fa-check"></i><b>15.4</b> Radiation dose from brachytherpay sources</a><ul>
<li class="chapter" data-level="15.4.1" data-path="brachy.html"><a href="brachy.html#from-exposure-rate"><i class="fa fa-check"></i><b>15.4.1</b> From exposure rate</a></li>
<li class="chapter" data-level="15.4.2" data-path="brachy.html"><a href="brachy.html#tg43"><i class="fa fa-check"></i><b>15.4.2</b> TG-43</a></li>
</ul></li>
<li class="chapter" data-level="15.5" data-path="brachy.html"><a href="brachy.html#ldr-solutions"><i class="fa fa-check"></i><b>15.5</b> Solutions</a></li>
<li class="chapter" data-level="15.6" data-path="brachy.html"><a href="brachy.html#traceability"><i class="fa fa-check"></i><b>15.6</b> Traceability</a></li>
<li class="chapter" data-level="15.7" data-path="brachy.html"><a href="brachy.html#tg-167-see-table-reftabtg167"><i class="fa fa-check"></i><b>15.7</b> TG-167 (see Table @ref(tab:tg167))</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="protection.html"><a href="protection.html"><i class="fa fa-check"></i><b>16</b> Radiation Protection</a><ul>
<li class="chapter" data-level="16.1" data-path="protection.html"><a href="protection.html#sources-of-radiation-exposure"><i class="fa fa-check"></i><b>16.1</b> Sources of radiation exposure</a></li>
<li class="chapter" data-level="16.2" data-path="protection.html"><a href="protection.html#stochastic-and-deterministic-event"><i class="fa fa-check"></i><b>16.2</b> Stochastic and deterministic event</a></li>
<li class="chapter" data-level="16.3" data-path="protection.html"><a href="protection.html#tds-rule"><i class="fa fa-check"></i><b>16.3</b> TDS rule</a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="qa.html"><a href="qa.html"><i class="fa fa-check"></i><b>17</b> QA</a><ul>
<li class="chapter" data-level="17.1" data-path="qa.html"><a href="qa.html#patient-specific-qa"><i class="fa fa-check"></i><b>17.1</b> Patient-specific QA</a></li>
<li class="chapter" data-level="17.2" data-path="qa.html"><a href="qa.html#quality-and-safety"><i class="fa fa-check"></i><b>17.2</b> Quality and safety</a></li>
</ul></li>
<li class="chapter" data-level="18" data-path="tbi.html"><a href="tbi.html"><i class="fa fa-check"></i><b>18</b> TBI</a></li>
<li class="chapter" data-level="19" data-path="crt.html"><a href="crt.html"><i class="fa fa-check"></i><b>19</b> Three-dimensional conformal radiotherapy</a><ul>
<li class="chapter" data-level="19.1" data-path="crt.html"><a href="crt.html#icru-reference-point"><i class="fa fa-check"></i><b>19.1</b> ICRU reference point</a></li>
<li class="chapter" data-level="19.2" data-path="crt.html"><a href="crt.html#image-registration"><i class="fa fa-check"></i><b>19.2</b> Image registration</a></li>
<li class="chapter" data-level="19.3" data-path="crt.html"><a href="crt.html#image-segmentation"><i class="fa fa-check"></i><b>19.3</b> Image segmentation</a></li>
<li class="chapter" data-level="19.4" data-path="crt.html"><a href="crt.html#cumulative-dvh"><i class="fa fa-check"></i><b>19.4</b> Cumulative DVH</a></li>
<li class="chapter" data-level="19.5" data-path="crt.html"><a href="crt.html#differential-dvh"><i class="fa fa-check"></i><b>19.5</b> Differential DVH</a></li>
</ul></li>
<li class="chapter" data-level="20" data-path="imrt.html"><a href="imrt.html"><i class="fa fa-check"></i><b>20</b> IMRT</a><ul>
<li class="chapter" data-level="20.1" data-path="imrt.html"><a href="imrt.html#imrt"><i class="fa fa-check"></i><b>20.1</b> IMRT</a></li>
<li class="chapter" data-level="20.2" data-path="imrt.html"><a href="imrt.html#psqa"><i class="fa fa-check"></i><b>20.2</b> IMRT QA</a></li>
<li class="chapter" data-level="20.3" data-path="imrt.html"><a href="imrt.html#transmission-or-leakage"><i class="fa fa-check"></i><b>20.3</b> Transmission or leakage</a></li>
<li class="chapter" data-level="20.4" data-path="imrt.html"><a href="imrt.html#q4-mu-imrt-vs.3dcrt"><i class="fa fa-check"></i><b>20.4</b> Q4 MU: IMRT vs. 3DCRT</a></li>
<li class="chapter" data-level="20.5" data-path="imrt.html"><a href="imrt.html#q5"><i class="fa fa-check"></i><b>20.5</b> Q5</a></li>
<li class="chapter" data-level="20.6" data-path="imrt.html"><a href="imrt.html#shielding-for-imrt"><i class="fa fa-check"></i><b>20.6</b> Shielding for IMRT</a></li>
<li class="chapter" data-level="20.7" data-path="imrt.html"><a href="imrt.html#section"><i class="fa fa-check"></i><b>20.7</b> </a></li>
<li class="chapter" data-level="20.8" data-path="imrt.html"><a href="imrt.html#q8"><i class="fa fa-check"></i><b>20.8</b> Q8</a></li>
<li class="chapter" data-level="20.9" data-path="imrt.html"><a href="imrt.html#q9"><i class="fa fa-check"></i><b>20.9</b> Q9</a></li>
<li class="chapter" data-level="20.10" data-path="imrt.html"><a href="imrt.html#q10"><i class="fa fa-check"></i><b>20.10</b> Q10</a></li>
<li class="chapter" data-level="20.11" data-path="imrt.html"><a href="imrt.html#mlc-tests"><i class="fa fa-check"></i><b>20.11</b> MLC test(s)</a></li>
<li class="chapter" data-level="20.12" data-path="imrt.html"><a href="imrt.html#q12"><i class="fa fa-check"></i><b>20.12</b> Q12</a></li>
</ul></li>
<li class="chapter" data-level="21" data-path="sbrt.html"><a href="sbrt.html"><i class="fa fa-check"></i><b>21</b> SBRT</a><ul>
<li class="chapter" data-level="21.1" data-path="sbrt.html"><a href="sbrt.html#milestones"><i class="fa fa-check"></i><b>21.1</b> Milestones</a></li>
<li class="chapter" data-level="21.2" data-path="sbrt.html"><a href="sbrt.html#the-definition-of-srs-and-sbrt"><i class="fa fa-check"></i><b>21.2</b> The definition of SRS and SBRT</a></li>
<li class="chapter" data-level="21.3" data-path="sbrt.html"><a href="sbrt.html#features-of-gamma-knife-perfexiontm-and-icontm"><i class="fa fa-check"></i><b>21.3</b> Features of GAMMA Knife Perfexion<sup>TM</sup> and Icon<sup>TM</sup></a><ul>
<li class="chapter" data-level="21.3.1" data-path="sbrt.html"><a href="sbrt.html#stereotactic-reference"><i class="fa fa-check"></i><b>21.3.1</b> Stereotactic reference</a></li>
<li class="chapter" data-level="21.3.2" data-path="sbrt.html"><a href="sbrt.html#steps-to-create-new-plan"><i class="fa fa-check"></i><b>21.3.2</b> Steps to create new plan</a></li>
</ul></li>
<li class="chapter" data-level="21.4" data-path="sbrt.html"><a href="sbrt.html#gk-white-papers"><i class="fa fa-check"></i><b>21.4</b> GK White Papers</a><ul>
<li class="chapter" data-level="21.4.1" data-path="sbrt.html"><a href="sbrt.html#accuracy-of-co-registration-of-planning-images-with-cone-beam-ct-images"><i class="fa fa-check"></i><b>21.4.1</b> Accuracy of co-registration of planning images with Cone Beam CT images</a></li>
<li class="chapter" data-level="21.4.2" data-path="sbrt.html"><a href="sbrt.html#automatic-positional-delivery-correction-using-a-stereotactic-cbct-in-gk-icontm"><i class="fa fa-check"></i><b>21.4.2</b> Automatic positional delivery correction using a stereotactic CBCT in GK Icon<sup>TM</sup></a></li>
</ul></li>
<li class="chapter" data-level="21.5" data-path="sbrt.html"><a href="sbrt.html#gk-troubleshooting"><i class="fa fa-check"></i><b>21.5</b> GK Troubleshooting</a></li>
<li class="chapter" data-level="21.6" data-path="sbrt.html"><a href="sbrt.html#qa-of-gk"><i class="fa fa-check"></i><b>21.6</b> QA of GK</a><ul>
<li class="chapter" data-level="21.6.1" data-path="sbrt.html"><a href="sbrt.html#prescision-and-accuracy"><i class="fa fa-check"></i><b>21.6.1</b> Prescision and accuracy</a></li>
</ul></li>
<li class="chapter" data-level="21.7" data-path="sbrt.html"><a href="sbrt.html#commissioning-of-gk"><i class="fa fa-check"></i><b>21.7</b> Commissioning of GK</a></li>
<li class="chapter" data-level="21.8" data-path="sbrt.html"><a href="sbrt.html#preparation-of-gk-treatment-planning"><i class="fa fa-check"></i><b>21.8</b> Preparation of GK Treatment Planning</a><ul>
<li class="chapter" data-level="21.8.1" data-path="sbrt.html"><a href="sbrt.html#frame-application-model-c"><i class="fa fa-check"></i><b>21.8.1</b> Frame Application: model C</a></li>
<li class="chapter" data-level="21.8.2" data-path="sbrt.html"><a href="sbrt.html#frame-application-perfexion"><i class="fa fa-check"></i><b>21.8.2</b> Frame application: Perfexion</a></li>
</ul></li>
<li class="chapter" data-level="21.9" data-path="sbrt.html"><a href="sbrt.html#gk-plan-indices"><i class="fa fa-check"></i><b>21.9</b> GK Plan Indices</a><ul>
<li class="chapter" data-level="21.9.1" data-path="sbrt.html"><a href="sbrt.html#systematic-errors"><i class="fa fa-check"></i><b>21.9.1</b> Systematic Errors</a></li>
</ul></li>
<li class="chapter" data-level="21.10" data-path="sbrt.html"><a href="sbrt.html#linac-based-srs"><i class="fa fa-check"></i><b>21.10</b> Linac-based SRS</a><ul>
<li class="chapter" data-level="21.10.1" data-path="sbrt.html"><a href="sbrt.html#cone-based"><i class="fa fa-check"></i><b>21.10.1</b> Cone-based</a></li>
</ul></li>
<li class="chapter" data-level="21.11" data-path="sbrt.html"><a href="sbrt.html#diesease-sites-treatment-with-srs"><i class="fa fa-check"></i><b>21.11</b> Diesease sites treatment with SRS</a><ul>
<li class="chapter" data-level="21.11.1" data-path="sbrt.html"><a href="sbrt.html#acoustic-neuoromas"><i class="fa fa-check"></i><b>21.11.1</b> Acoustic neuoromas</a></li>
<li class="chapter" data-level="21.11.2" data-path="sbrt.html"><a href="sbrt.html#arteriovenous-malforamtions-avm"><i class="fa fa-check"></i><b>21.11.2</b> Arteriovenous malforamtions (AVM)</a></li>
<li class="chapter" data-level="21.11.3" data-path="sbrt.html"><a href="sbrt.html#brain-metastases"><i class="fa fa-check"></i><b>21.11.3</b> Brain metastases</a></li>
<li class="chapter" data-level="21.11.4" data-path="sbrt.html"><a href="sbrt.html#malignant-gliomas"><i class="fa fa-check"></i><b>21.11.4</b> Malignant gliomas</a></li>
<li class="chapter" data-level="21.11.5" data-path="sbrt.html"><a href="sbrt.html#menningiomas"><i class="fa fa-check"></i><b>21.11.5</b> Menningiomas</a></li>
<li class="chapter" data-level="21.11.6" data-path="sbrt.html"><a href="sbrt.html#pituitary-tumors"><i class="fa fa-check"></i><b>21.11.6</b> Pituitary tumors</a></li>
<li class="chapter" data-level="21.11.7" data-path="sbrt.html"><a href="sbrt.html#unilateral-vestibular-schwannomas"><i class="fa fa-check"></i><b>21.11.7</b> Unilateral Vestibular Schwannomas</a></li>
<li class="chapter" data-level="21.11.8" data-path="sbrt.html"><a href="sbrt.html#uveal-melanomas"><i class="fa fa-check"></i><b>21.11.8</b> Uveal melanomas</a></li>
<li class="chapter" data-level="21.11.9" data-path="sbrt.html"><a href="sbrt.html#trigeminal-neuralgia"><i class="fa fa-check"></i><b>21.11.9</b> Trigeminal neuralgia</a></li>
</ul></li>
<li class="chapter" data-level="21.12" data-path="sbrt.html"><a href="sbrt.html#dose-fall-off"><i class="fa fa-check"></i><b>21.12</b> Dose fall-off</a></li>
<li class="chapter" data-level="21.13" data-path="sbrt.html"><a href="sbrt.html#required-measurements-for-commissioning-a-srssbrt-program"><i class="fa fa-check"></i><b>21.13</b> Required measurements for commissioning a SRS/SBRT program</a></li>
</ul></li>
<li class="chapter" data-level="22" data-path="hdr.html"><a href="hdr.html"><i class="fa fa-check"></i><b>22</b> HDR</a><ul>
<li class="chapter" data-level="22.1" data-path="hdr.html"><a href="hdr.html#hdr-vs.ldr"><i class="fa fa-check"></i><b>22.1</b> HDR vs. LDR</a></li>
<li class="chapter" data-level="22.2" data-path="hdr.html"><a href="hdr.html#common-indications-in-practice"><i class="fa fa-check"></i><b>22.2</b> Common indications in practice</a></li>
<li class="chapter" data-level="22.3" data-path="hdr.html"><a href="hdr.html#hdr-qa"><i class="fa fa-check"></i><b>22.3</b> HDR-QA</a><ul>
<li class="chapter" data-level="22.3.1" data-path="hdr.html"><a href="hdr.html#daily-qa"><i class="fa fa-check"></i><b>22.3.1</b> Daily QA</a></li>
<li class="chapter" data-level="22.3.2" data-path="hdr.html"><a href="hdr.html#pretreatment-qa-tg-59"><i class="fa fa-check"></i><b>22.3.2</b> Pretreatment QA (TG-59)</a></li>
<li class="chapter" data-level="22.3.3" data-path="hdr.html"><a href="hdr.html#hdr-source-change"><i class="fa fa-check"></i><b>22.3.3</b> Source change</a></li>
</ul></li>
<li class="chapter" data-level="22.4" data-path="hdr.html"><a href="hdr.html#medical-events"><i class="fa fa-check"></i><b>22.4</b> Medical Events</a></li>
<li class="chapter" data-level="22.5" data-path="hdr.html"><a href="hdr.html#source"><i class="fa fa-check"></i><b>22.5</b> Source</a></li>
<li class="chapter" data-level="22.6" data-path="hdr.html"><a href="hdr.html#treatment-sites-1"><i class="fa fa-check"></i><b>22.6</b> Treatment sites</a><ul>
<li class="chapter" data-level="22.6.1" data-path="hdr.html"><a href="hdr.html#endometrial-cancer"><i class="fa fa-check"></i><b>22.6.1</b> Endometrial cancer</a></li>
<li class="chapter" data-level="22.6.2" data-path="hdr.html"><a href="hdr.html#cervical"><i class="fa fa-check"></i><b>22.6.2</b> Cervical cancer</a></li>
<li class="chapter" data-level="22.6.3" data-path="hdr.html"><a href="hdr.html#breast"><i class="fa fa-check"></i><b>22.6.3</b> Breast</a></li>
<li class="chapter" data-level="22.6.4" data-path="hdr.html"><a href="hdr.html#prostate"><i class="fa fa-check"></i><b>22.6.4</b> Prostate</a></li>
</ul></li>
<li class="chapter" data-level="22.7" data-path="hdr.html"><a href="hdr.html#references"><i class="fa fa-check"></i><b>22.7</b> References</a></li>
<li class="chapter" data-level="22.8" data-path="hdr.html"><a href="hdr.html#solutions-3"><i class="fa fa-check"></i><b>22.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="23" data-path="implants.html"><a href="implants.html"><i class="fa fa-check"></i><b>23</b> Implants</a><ul>
<li class="chapter" data-level="23.1" data-path="implants.html"><a href="implants.html#isotopes-1"><i class="fa fa-check"></i><b>23.1</b> Isotopes</a></li>
<li class="chapter" data-level="23.2" data-path="implants.html"><a href="implants.html#patient-release"><i class="fa fa-check"></i><b>23.2</b> Patient Release</a></li>
<li class="chapter" data-level="23.3" data-path="implants.html"><a href="implants.html#prostate-implants"><i class="fa fa-check"></i><b>23.3</b> Prostate implants</a></li>
<li class="chapter" data-level="23.4" data-path="implants.html"><a href="implants.html#y90"><i class="fa fa-check"></i><b>23.4</b> TheraSphere</a></li>
</ul></li>
<li class="chapter" data-level="24" data-path="ivbt.html"><a href="ivbt.html"><i class="fa fa-check"></i><b>24</b> Intravascular BT</a></li>
<li class="chapter" data-level="25" data-path="igrt.html"><a href="igrt.html"><i class="fa fa-check"></i><b>25</b> IGRT</a></li>
<li class="chapter" data-level="26" data-path="cyber-knife.html"><a href="cyber-knife.html"><i class="fa fa-check"></i><b>26</b> Cyber Knife</a></li>
<li class="chapter" data-level="27" data-path="proton.html"><a href="proton.html"><i class="fa fa-check"></i><b>27</b> Proton RT</a></li>
<li class="chapter" data-level="28" data-path="varian.html"><a href="varian.html"><i class="fa fa-check"></i><b>28</b> Varian</a><ul>
<li class="chapter" data-level="28.1" data-path="varian.html"><a href="varian.html#clinac-couch"><i class="fa fa-check"></i><b>28.1</b> Clinac couch</a></li>
</ul></li>
<li class="chapter" data-level="29" data-path="it.html"><a href="it.html"><i class="fa fa-check"></i><b>29</b> Information Technology</a><ul>
<li class="chapter" data-level="29.1" data-path="it.html"><a href="it.html#it-basics"><i class="fa fa-check"></i><b>29.1</b> IT basics</a></li>
<li class="chapter" data-level="29.2" data-path="it.html"><a href="it.html#dicom"><i class="fa fa-check"></i><b>29.2</b> DICOM</a></li>
<li class="chapter" data-level="29.3" data-path="it.html"><a href="it.html#database-basics"><i class="fa fa-check"></i><b>29.3</b> Database basics</a></li>
<li class="chapter" data-level="29.4" data-path="it.html"><a href="it.html#programming"><i class="fa fa-check"></i><b>29.4</b> Programming</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">MP</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="hdr" class="section level1">
<h1><span class="header-section-number">Chapter 22</span> HDR</h1>
<div id="hdr-vs.ldr" class="section level2">
<h2><span class="header-section-number">22.1</span> HDR vs. LDR</h2>
<p>LDR: well-established treatment; standard doses, plan, and treatmetn time<a href="#fn21" class="footnoteRef" id="fnref21"><sup>21</sup></a><br />
HDR: Outpatient treatment, short administration time, minimal staff exposure, standard source strength, and dose optimization</p>
</div>
<div id="common-indications-in-practice" class="section level2">
<h2><span class="header-section-number">22.2</span> Common indications in practice</h2>
<ul>
<li>GYN (cervical<a href="#fn22" class="footnoteRef" id="fnref22"><sup>22</sup></a>, uterine, vaginal, vulvar)</li>
<li>Prostate (monotherapy or boost)</li>
<li>Breast (accelerated partial breast irradiation)</li>
<li>possible Sarcoma, skin, esophagus, and bile duct</li>
</ul>
<p>?? Theoretically, HDR has a lower therapeutic ratio than LDR because of the short duration of the treatments. How? - Practical ROP chapter “Intracavitary Brachytherapy”</p>
</div>
<div id="hdr-qa" class="section level2">
<h2><span class="header-section-number">22.3</span> HDR-QA</h2>
<div id="daily-qa" class="section level3">
<h3><span class="header-section-number">22.3.1</span> Daily QA</h3>
<p>According <a href="https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0643.html">10 CFR35.643</a>, the AMP needs to review the daily QA within <strong>15 days</strong>.</p>
</div>
<div id="pretreatment-qa-tg-59" class="section level3">
<h3><span class="header-section-number">22.3.2</span> Pretreatment QA (TG-59)</h3>
<ol style="list-style-type: decimal">
<li>Two people (therapists?) should check proper <strong>connection of catheters</strong> to the HDR unit and that the transfer tubes are free of kinks.</li>
<li>The emergency kit and source container are available.</li>
<li>Survey meter and/or GM-counter is present and operational. (The patient may have had a nuclear medicine scan prior to the treatment, causing an elevated reading. thus a <strong>pre-treatment survey</strong> is conducted though not listed in TG-59).</li>
<li>The <strong>length</strong> of transfer tube and applicator (catheters) are correct.</li>
<li>Check applicator positioning. How do physicians check this item without image verification?</li>
<li>Treatment documentation review.
<ol style="list-style-type: lower-alpha">
<li>Signed prescription and plan.</li>
<li>Second check has been performed. (use emipircal values)</li>
<li>Plan agrees with prescription.</li>
<li>Plan is consistent with previous fractions if applicable.</li>
<li>Dwell positions and times in plan agree with what is programmed on the treatment console.</li>
</ol></li>
<li>Patient identity confirmed by two methods.</li>
</ol>
<p>At current practice, a <strong>check-list</strong> is used by physicists for pretrement plan QA and a time-out is conducted prior to initiating the treatment.</p>
</div>
<div id="hdr-source-change" class="section level3">
<h3><span class="header-section-number">22.3.3</span> Source change</h3>
<p>The half-life time is about 74 days, so the old source is sawpped with a new source about every 3 months. The activity of the new source is normally about <strong>10 Ci</strong>. According to Eq. <a href="brachy.html#eq:sk">(15.1)</a> and Eq. <a href="brachy.html#eq:exposure">(15.2)</a>, it is equal to 41100 U (<span class="math inline">\(S_k = 10,000\ (mCi) \times 4.69 \left(\frac{{R\cdot cm}^2}{mCi\cdot hr} \right) \times 0.876 \left(\frac{cGy}{R}\right)\)</span>). This quantity will be verified by an autheried medical physicist (<strong>AMP</strong>) using NIST tracable well chamber and electrometer, and then enterred in the treatment planning system for dose calculation. The engineering from HDR afterloader vendor also verifies the source using their own equipment.</p>
<ol style="list-style-type: decimal">
<li>Verify the source cable <strong>positioning accuracy</strong> at two different programmed positions (1205 mm and 1400 mm) before the vendor engineering leaves (using GYN transfer tube).</li>
<li>Although the well chamber and electrometer is still within 2-year calibration period, we always do <strong>consistence check</strong> using a NIST-traceble Cs-137 source (we actually checked with 2 Cs-137 sources provided by our RSO).</li>
<li>Switch a physics QA transfer tube and insert a catheter into Ir-192 insert.</li>
<li>Measure current at 5 positions (1195 mm, 1200 mm, 1205 mm, 1210 mm, and 1215 mm) and take an average</li>
<li>Check time-dose linearity</li>
<li>Check stopwatch accuracy (100 s)</li>
<li>Check transfer tube connection error</li>
<li>Switch emergency power switch</li>
<li>Check</li>
</ol>
</div>
</div>
<div id="medical-events" class="section level2">
<h2><span class="header-section-number">22.4</span> Medical Events</h2>
<ul>
<li><a href="http://www.nrc.gov/reading-rm/doccollections/nuregs/brochures/br0117/">Errors on NRC website</a></li>
<li><a href="(http://chapter.aapm.org/GLC/media/2011/tollenaar.pdf)">Wisconsin</a></li>
</ul>
</div>
<div id="source" class="section level2">
<h2><span class="header-section-number">22.5</span> Source</h2>
<p>A comprehensive seed data source can be found from a <a href="http://www.physics.carleton.ca/clrp/seed_database">database</a> provided by Carleton University</p>
<p>Because <a href="https://www.estro.org/about/governance-organisation/committees-activities/tg43-ir-192-hdr">Ir-192</a> has much higher <code>special activity</code> than most other isotopes, it is now the mostly used radio-isotope for HDR treatment. The higher the special activity means that the Ir-192 can be made with small physial dimension but still provide high radioactivity.</p>
<p>The special activity (SA) is defined as the activity per mass. It depends on half lifetime and atomic number, <span class="math inline">\(SA \propto \frac{1}{T_{1/2}\cdot A}\)</span>. For example, <span class="math inline">\(\frac{SA_{Co}}{SA_{Ir}} = \frac{74\ days \times 192}{5\ years \times 60} \approx 0.13\)</span>. Wait a second, how about SA of I-125? Although I-125 can have higher SA than Ir-192, the energy of I-125 is just too low for enough tissue penetration.</p>
<p>Co-60 has been used recently!</p>
</div>
<div id="treatment-sites-1" class="section level2">
<h2><span class="header-section-number">22.6</span> Treatment sites</h2>
<div id="endometrial-cancer" class="section level3">
<h3><span class="header-section-number">22.6.1</span> Endometrial cancer</h3>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111003874?via%3Dihub">ABS consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy</a></p>
<ul>
<li>Dose fractionation: 7Gy <span class="math inline">\(\times\)</span> 3 prescribed to 0.5 cm is a common fractionation scheme with active length of 5 cm (<span class="math inline">\(\color{Purple} {\text{Are we treating vaginal cuff or the whole vigina?}}\)</span>)</li>
<li>the standard applicator is a segmented cylinder with one central catheter; the <strong>largest diameter</strong> cylinder that patient can tolerate is used to minimize the air gap between cylinder and vagina and to avoid rapid dose fall-off.</li>
</ul>
</div>
<div id="cervical" class="section level3">
<h3><span class="header-section-number">22.6.2</span> Cervical cancer</h3>
<ul>
<li><a href="">ABS consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles</a></li>
<li><a href="https://www.sciencedirect.com/science/article/pii/S1538472111003515">ABS consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy</a></li>
</ul>
<p>Cervical cancer is mostly treated with HDR brachytherapy.</p>
<ul>
<li>1903 Stockholm and Paris</li>
<li>1938 Manchester – point A</li>
<li>1953 Point A revision</li>
<li>1985 ICRU 38</li>
<li>1987 more point A updates</li>
<li>2000 GEC-ESTRO
<ul>
<li>D90, D100 for dose prescription</li>
<li>D2cc bladder, rectum, and sigmoid</li>
</ul></li>
<li>2004 GTV and CTV delineation (MRI)</li>
<li>2005 GEC-ESTRO recommendation for IGRT brachytherapy</li>
</ul>
<blockquote>
<p>Improvement occurred only in tumours &gt;5 cm: OS 28% versus 58% (p = 0.003) - R. Potter (2007) in “Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer”.</p>
</blockquote>
<p><strong>GEC-ESTRO target volumes</strong><a href="#fn23" class="footnoteRef" id="fnref23"><sup>23</sup></a></p>
<ul>
<li><code>Gross tumor volume (diagnosis)</code> (GTV<sub>D</sub>)
<ul>
<li><strong>macroscopic</strong> tumor extension at diagnosis</li>
<li>detected by clinical examination and as visualized on MRI (high signal intensity mass(es) at <em>fast spine echo</em> (FSE) sequences T2 in cervix/corpus, parametria, vagina, bladder, and rectum)</li>
</ul></li>
<li><code>Gross tumor volume (brachy)</code> (GTV<sub>B1</sub>, GTV<sub>B2</sub>, …)
<ul>
<li><strong>macroscopic</strong> tumor volume at time of brachy</li>
<li>detected by clinical examination and as visualized on MRI</li>
</ul></li>
<li><code>High risk CTV</code> (HR CTV<sub>B1</sub>, HR CTV<sub>B2</sub>, …)
<ul>
<li>includes GTV<sub>Bx</sub> and the whole cervix or MRI grey zones?</li>
<li>represent <strong>macroscopic</strong> tumor load</li>
</ul></li>
<li><code>Intermediate risk CTV</code> (IR CTV<sub>B1</sub>, IR CTV<sub>B2</sub>, …)
<ul>
<li>areas with a significant <strong>microscopic disease</strong></li>
<li>IR CTV = HR CTV + 5-15 mm margin for limited diseases</li>
<li>based on GTV<sub>D</sub> for extensive disease</li>
</ul></li>
</ul>
<p><strong>Applicator imaging</strong></p>
<p><strong>Idea</strong>: availability of commercial dummy sources for MRI is limited.</p>
<p>Based on GEC-ESTRO recommendations<a href="#fn24" class="footnoteRef" id="fnref24"><sup>24</sup></a>, the choice of MR sequence is essential for optimal visualisation of the applicator. There are difference between plastic and titanium applicators<a href="#fn25" class="footnoteRef" id="fnref25"><sup>25</sup></a></p>
<ul>
<li>Plastic has weak signal on T2; use of markers</li>
<li>Titanium has (induced) susceptibility artifact, and thus more distortions for higher magnetic strength; worse on T2; T1 is more suitable (? Why Titanium is MR compatible? )</li>
<li>If an applicator has been shown to be MR conditional for a 1.5T MRI, then it does <strong>not</strong> mean that it can be safely used in a 3T system without the need for further testing. CT still provides best imaging for applicator in terms of spatial accuracy (1 mm on CT vs. 1-2 mm on MRI for the localization of first dwell position) and artifacts.</li>
</ul>
<p><strong>Prescription Dose</strong></p>
<ul>
<li>HDR prescription: 5.5 Gy <span class="math inline">\(\times\)</span> 5, 6 Gy <span class="math inline">\(\times\)</span> 5, or 7 Gy <span class="math inline">\(\times\)</span> 4; once a week</li>
<li>HR CTV: total dose &gt; 85 Gy <strong>Can we go higher? or fewer fractions</strong></li>
<li>IR CTV: 60 Gy</li>
</ul>
</div>
<div id="breast" class="section level3">
<h3><span class="header-section-number">22.6.3</span> Breast</h3>
<p>ABS acceptability criteria for APBI</p>
<ul>
<li>Age: <span class="math inline">\(\ge\)</span> 50 year old</li>
<li>Size: <span class="math inline">\(\le\)</span> 3 cm</li>
<li>Histology: All invasive subtypes and DCIS</li>
<li>Estrogen receptor: +/-</li>
<li>Surgical margin: -</li>
<li>Lymphovasucular space invasion: not present</li>
<li>Nodal status: -</li>
</ul>
<p>Treatment planning</p>
<ul>
<li>34 Gy in 10 fractions twice daily</li>
<li>PTV<sub>Eval</sub> + D90% &gt;= 90% + V150 &lt; 50 cm<sup>3</sup> + V200 &lt; 10 cm<sup>3</sup> + Skin dose &lt; 145% of prescription</li>
</ul>
<p>They are slightly different from ASTRO Consensus Statement 2009.</p>
</div>
<div id="prostate" class="section level3">
<h3><span class="header-section-number">22.6.4</span> Prostate</h3>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111004004">ABS consensus guidelines for high-dose-rate prostate brachytherapy</a></p>
<p>Monotherapy: 13.5 Gy <span class="math inline">\(\times\)</span> 2 fractions (NCCN)</p>
</div>
</div>
<div id="references" class="section level2">
<h2><span class="header-section-number">22.7</span> References</h2>
<ul>
<li><a href="https://www.aapm.org/pubs/reports/rpt_41.pdf">TG-41 (1993)</a> Remote Afterloading Technology.</li>
<li><a href="https://www.aapm.org/pubs/reports/detail.asp?docid=50">TG-43 (1995)</a> Dosimetry of Interstitial Brachytherapy Sources.</li>
<li>TG-43U (2004) A revised AAPM protocol for brachytherapy dose calculations.</li>
<li><a href="https://www.aapm.org/pubs/reports/detail.asp?docid=58#">TG-56 (1997)</a> Code of practice for brachytherapy physics.</li>
<li><a href="https://pdfs.semanticscholar.org/5a32/c14e0720d3e5af0747e5a191845683b3feca.pdf">TG-59 (1998)</a> High dose-rate brachytherapy treatment delivery.</li>
<li><a href="https://www.aapm.org/pubs/reports/detail.asp?docid=167">AAPM UN-25 (2017)</a> Supplement 2 for the 2004 update of the AAPM Task Group No. 43 Report: Joint recommendations by the AAPM and GEC-ESTRO.</li>
<li>ABS guideline: <a href="https://www.americanbrachytherapy.org/guidelines/cervical_cancer_taskgroup.pdf" class="uri">https://www.americanbrachytherapy.org/guidelines/cervical_cancer_taskgroup.pdf</a>.</li>
<li>Damato AL, Lee LJ, Bhagwat MS, et al. Redesign of process map to increase efficiency: Reducing procedure time in cervical cancer brachytherapy. Brachytherapy. 2015;14:471–480.</li>
<li>Dose Optimization in Gynecological 3D Image Based Interstitial Brachytherapy using Martinez Universal Perineal Interstitial Template (MUPIT) -An Institutional Experience. J Med Phys (2014) 39 (3): 197-202.</li>
<li>Kim et al., “Evaluation of artifacts and distortions of titanium applicators on 3.0-Tesla MRI: Feasibility of titanium applicators in MRI-guided brachytherapy for gynecological cancer,” Int J Radiation Oncology, 80 (3), 947-55 (2011).</li>
</ul>
</div>
<div id="solutions-3" class="section level2">
<h2><span class="header-section-number">22.8</span> Solutions</h2>
<p><strong>Q1 Dose rate</strong> c)<br />
<strong>Q2</strong> a)<br />
<strong>Q3 TG43U </strong> d)</p>
Using Eq. @ref(eq.tg43) or TG-43U1 2D Brachytherapy dosimetry formalism,
<span class="math display">\[\begin{equation}
\begin{aligned}
   \dot D(r, \theta) &amp;= \Lambda\cdot S_k \frac{G_L(r, \theta)}{G_L(r=1cm,\theta=90^o)} \cdot g_L(r, \theta)\cdot F(r,\theta)\\
   &amp;=1.12\ cGy/(h\cdot U)\cdot4.11\times10^4\text{U}\cdot1.023\cdot1\\
   &amp;=\boxed{13.1\ cGy/s}
\end{aligned}
\end{equation}\]</span>
<p><strong>Q4 Afterloader QA</strong> a)<br />
<strong>Q5 Shiedling</strong> b)<br />
<strong>Q6 Impact of decay on treatment timee</strong></p>
The half-life time of Ir-192 is about 74 days, so activity after 90 days (Eq. (<a href="#eq:decay2">(<strong>??</strong>)</a>)) is
<span class="math display">\[\begin{equation*}
    A_2 = A_02^{-t/T_{1/2}}=A_02^{-90/74}=0.43A_1
\end{equation*}\]</span>
<p>To maintain the prescribed dose (<span class="math inline">\(\dot D_1 \Delta t_1 = \dot D_2 \Delta t_2\)</span> and <span class="math inline">\(A \propto \dot D\)</span>, the dwell time <span class="math inline">\(\Delta t_2\)</span> will be</p>
<span class="math display">\[\begin{equation*} 
{\Delta t_2 = \frac{\dot D_1}{\dot D_2} \Delta t_1 = \frac{\dot A_1}{\dot A_2} \Delta t_1 = \frac{1}{0.43}\times 16 \text{ min} \ \times 80\% = \boxed{29.7 \text{ min}}}
\end{equation*}\]</span>
<p>The total treatment time will be <span class="math inline">\(29.7 + 16\times20\%=\boxed{33\ \text{minutes}}\)</span>.</p>
<p><strong>Q7</strong> c)<br />
<strong>Q8</strong> c)<br />
<strong>Q9</strong> b) <strong>Q10</strong> a) but esophagus cancer is also treated with HDR but with less indication`<br />
<strong>Q11</strong> b)<br />
<strong>Q12</strong> d)</p>

</div>
</div>
<div class="footnotes">
<hr />
<ol start="22">
<li id="fn22"><p><a href="http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD007563.pub2/abstract">Cochrane review</a> and its <a href="https://www.ncbi.nlm.nih.gov/m/pubmed/25300170/?i=5&amp;from=/10432431/related">update</a>: there is no difference in OS, DSS, LC, nodal occurrence, distance occurrence was found between LDR and HDR (from a meta-analysis of 4 clinical trials in <em>Cochrane database</em> with a total of 1265 patients with advanced cervical cancer), but HDR is more convenient and accurate.<a href="hdr.html#fnref22">↩</a></p></li>
<li id="fn23"><p>Schwarz 2015 AAPM Spring Clinical Meeting “Defining Targets for Brachytherapy” <a href="https://www.aapm.org/education/vl/vl.asp?id=4077" class="uri">https://www.aapm.org/education/vl/vl.asp?id=4077</a><a href="hdr.html#fnref23">↩</a></p></li>
<li id="fn24"><p><a href="https://www.sciencedirect.com/science/article/pii/S0167814010003683">Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy</a><a href="hdr.html#fnref24">↩</a></p></li>
<li id="fn25"><p>Haack et al 2009 Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. <a href="https://doi.org/10.1016/j.radonc.2008.09.002" class="uri">https://doi.org/10.1016/j.radonc.2008.09.002</a><a href="hdr.html#fnref25">↩</a></p></li>
</ol>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="sbrt.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="implants.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"linkedin": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"download": ["MP.pdf", "MP.epub"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "";
    if (src === "" || src === "true") src = "https://cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:" && /^https?:/.test(src))
      src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
